These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

488 related items for PubMed ID: 25764148

  • 21. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.
    Gattermann N, Finelli C, Porta MD, Fenaux P, Ganser A, Guerci-Bresler A, Schmid M, Taylor K, Vassilieff D, Habr D, Domokos G, Roubert B, Rose C, EPIC study investigators.
    Leuk Res; 2010 Sep; 34(9):1143-50. PubMed ID: 20451251
    [Abstract] [Full Text] [Related]

  • 22. Iranian experience of deferasirox (Exjade(®)) in transfusion-dependent patients with iron overload: what is the most effective dose based on serum ferritin levels?
    Karimi M, Azarkeivan A, Zareifar S, Cohan N, Bordbar MR, Haghpanah S.
    Hematology; 2012 Nov; 17(6):367-71. PubMed ID: 23168076
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
    Delforge M, Selleslag D, Triffet A, Mineur P, Bries G, Graux C, Trullemans F, MacDonald K, Abraham I, Pluymers W, Ravoet C.
    Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
    [Abstract] [Full Text] [Related]

  • 27. Hematopoietic recovery after administration of deferasirox for transfusional iron overload in a case of myelodysplastic syndrome.
    OKABE H, SUZUKI T, OMORI T, MORI M, UEHARA E, HATANO K, UEDA M, MATSUYAMA T, TOSHIMA M, QZAKI K, NAGAI T, MUROI K, OZAWA K.
    Rinsho Ketsueki; 2009 Nov; 50(11):1626-9. PubMed ID: 20009438
    [Abstract] [Full Text] [Related]

  • 28. Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.
    Karimi M, Arandi N, Haghpanah S, Ansari S, Azarkeyvan A, Bordbar M, Safaei S.
    Hemoglobin; 2015 Nov; 39(5):327-9. PubMed ID: 26114738
    [Abstract] [Full Text] [Related]

  • 29. Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia.
    Lee SE, Yahng SA, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Kim HJ, Cho SG, Kim DW, Min WS, Park CW, Lee JW.
    Acta Haematol; 2013 Nov; 129(2):72-7. PubMed ID: 23154600
    [Abstract] [Full Text] [Related]

  • 30. Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients.
    Tolley K, Oliver N, Miranda E, Migliaccio-Walle K, Bozkaya D, Li Q.
    J Med Econ; 2010 Nov; 13(3):559-70. PubMed ID: 20812793
    [Abstract] [Full Text] [Related]

  • 31. Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.
    Remacha AF, Arrizabalaga B, Del Cañizo C, Sanz G, Villegas A.
    Ann Hematol; 2010 Feb; 89(2):147-54. PubMed ID: 19690857
    [Abstract] [Full Text] [Related]

  • 32. Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy.
    Jabbour E, Garcia-Manero G, Taher A, Kantarjian HM.
    Oncologist; 2009 May; 14(5):489-96. PubMed ID: 19365094
    [Abstract] [Full Text] [Related]

  • 33. Elevated total iron-binding capacity as a predictor of response to deferasirox therapy in the setting of chronic iron overload.
    Watanabe J, Sato K, Horiuchi T, Kato S, Hikota R, Maekawa T, Yamamura T, Kobayashi A, Osawa Y, Kobayashi S, Kimura F.
    Int J Hematol; 2014 Sep; 100(3):254-9. PubMed ID: 24986748
    [Abstract] [Full Text] [Related]

  • 34. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.
    Leitch HA.
    Leuk Res; 2007 Dec; 31 Suppl 3():S7-9. PubMed ID: 18037416
    [Abstract] [Full Text] [Related]

  • 35. Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes.
    Greenberg PL, Koller CA, Cabantchik ZI, Warsi G, Glynos T, Paley C, Schiffer C.
    Leuk Res; 2010 Dec; 34(12):1560-5. PubMed ID: 20615548
    [Abstract] [Full Text] [Related]

  • 36. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
    Cassinerio E, Orofino N, Roghi A, Duca L, Poggiali E, Fraquelli M, Zanaboni L, Cappellini MD.
    Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
    [Abstract] [Full Text] [Related]

  • 37. [Curative effects and safety of deferasirox in treatment of iron overload in children with β-thalassemia major].
    Gao HY, Li Q, Chen JJ, Chen GF, Li CG.
    Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jul; 13(7):531-4. PubMed ID: 21752315
    [Abstract] [Full Text] [Related]

  • 38. CONIFER - Non-Interventional Study to Evaluate Therapy Monitoring During Deferasirox Treatment of Iron Toxicity in Myelodysplastic Syndrome Patients with Transfusional Iron Overload.
    Bruch HR, Dencausse Y, Heßling J, Michl G, Schlag R, Skorupa A, Schneider-Schranz C, Wolf S, Schulte C, Tesch H.
    Oncol Res Treat; 2016 Jul; 39(7-8):424-31. PubMed ID: 27486873
    [Abstract] [Full Text] [Related]

  • 39. Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes.
    Ricchi P, Marsella M.
    Drug Des Devel Ther; 2015 Jul; 9():6475-82. PubMed ID: 26719673
    [Abstract] [Full Text] [Related]

  • 40. Iron chelation therapy in MDS: what have we learnt recently?
    Schmid M.
    Blood Rev; 2009 Dec; 23 Suppl 1():S21-5. PubMed ID: 20116636
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.